- Home
- DBVT vs ETON Comparison
DBVT vs ETON Comparison
Compare DBVT & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBVT | ETON |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.0M | 498.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | DBVT | ETON |
|---|---|---|
| Price | $13.02 | $16.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $15.85 | ★ $29.67 |
| AVG Volume (30 Days) | 118.6K | ★ 316.5K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,502,000.00 | ★ $70,316,000.00 |
| Revenue This Year | $1,743.46 | $105.25 |
| Revenue Next Year | $1,045.66 | $40.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 102.77 |
| 52 Week Low | $2.70 | $11.09 |
| 52 Week High | $18.00 | $23.00 |
Technical Indicators
Market Signals| Indicator | DBVT | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 36.52 |
| Support Level | $12.70 | $15.62 |
| Resistance Level | $14.68 | $16.89 |
| Average True Range (ATR) | 0.93 | 0.79 |
| MACD | -0.14 | -0.09 |
| Stochastic Oscillator | 21.86 | 14.63 |
Price Performance
Historical ComparisonAbout DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.